Market Analysis: Global Guillain-Barré Syndrome (GBS) Market

Global guillain-barré syndrome (GBS) market is set to witness substantial CAGR of 5.2% in the forecast period of 2019- 2026. The report contains data of the base year 2018 and historic year 2017. Rising healthcare expenditure and increasing cases of GBS are the major factor for the growth of this market.

Market Definition: Global Guillain-Barré Syndrome (GBS) Market

GBS or guillain-barré syndrome is a condition when the immune system of the body starts attacking the body’s nerves. This disease can cause numbness, weakness and tingling and in some cases can cause paralysis. Some of the common types of the GBS are miller fisher syndrome, acute inflammatory demyelinating polyradiculoneuropathy and acute motor axonal neuropathy. This situation cannot be cured but there is      some treatments which can reduce the duration of the illness. Some of the treatments are medication, physical therapy, hydrotherapy, medications and others.

Get Sample Analysis of Global Market Information: https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-guillain-barr-syndrome-gbs-market

Market Drivers

Technological advancement and development in healthcare industry will accelerate the market growth
Rising support and funding from government will also drive the growth of this market
Increasing approvals of immunoglobulins from regulatory bodies will also enhance the growth of this market
Rising usage of IVIG in off-label indications is another factor contributing as a factor as the market growth

Market Restraints

Lack of awareness about disease will restrain the market growth
Unavailability of any proper treatment will also hinder the growth of this market
Segmentation: Global Guillain-Barré Syndrome (GBS) Market

By Therapeutics

Intravenous Immunoglobulin
Plasma Exchange
Others
Analgesics
Anticonvulsants
LMWH

By Route of Administration

Oral
Parenteral

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Other

By Type

Acute Inflammatory Demyelinating Polyradiculoneuropathy
Miller Fisher Syndrome
Acute Motor Axonal Neuropathy
Others

By Diagnosis

Lumbar Puncture
Electromyography
Nerve Conduction
Others

By Treatment

Plasmapheresis
Medication
Physical Therapy
Hydrotherapy

By Geography

North America
U.S.
Canada
Mexico
Europe
Germany
Italy
U.K.
France
Spain
Netherlands
Belgium
Switzerland
Turkey
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
South Korea
Australia
Singapore
Malaysia
Thailand
Indonesia
Philippines
Rest of Asia-Pacific
South America
Brazil
Rest of South America
Middle East and Africa
South Africa
Rest of Middle East and Africa

Get TOC of Full Report: https://www.databridgemarketresearch.com/toc/?dbmr=global-guillain-barr-syndrome-gbs-market

Key Development in the Market:

In April 2019, Hansa Biopharma AB announced that they have received Clinical Trial Application and Ethics Committee approvals in Europe for their Phase 2 study of imlifidase in Guillain Barré Syndrome (GBS).This new IgG degrading enzyme, imlifidase, has ability in different acute autoimmune diseases, including Guillain Barré Syndrome

Competitive Analysis:

Global guillain-barré syndrome (GBS) market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of guillain-barré syndrome (GBS) market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Competitors:

Few of the major competitors currently working in the global guillain-barré syndrome (GBS) market are Grifols, S.A., CSL, Octapharma, Akari Therapeutics, Kedrion S.p.A., Hansa Biopharma AB among others.